

Frederik MarmÃ©

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5549940/publications.pdf>

Version: 2024-02-01

125
papers

7,213
citations

117453

34
h-index

62479

80
g-index

128
all docs

128
docs citations

128
times ranked

10638
citing authors

#	ARTICLE	IF	CITATIONS
1	Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2416-2428.	13.9	1,176
2	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. <i>Nature Genetics</i> , 2013, 45, 353-361.	9.4	960
3	⁶⁸ Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. <i>Journal of Nuclear Medicine</i> , 2019, 60, 801-805.	2.8	874
4	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. <i>Nature Genetics</i> , 2015, 47, 373-380.	9.4	513
5	Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1421-1429.	2.8	281
6	Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer- The Penelope-B Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 1518-1530.	0.8	153
7	Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. <i>Human Molecular Genetics</i> , 2011, 20, 3289-3303.	1.4	152
8	Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study. <i>BMC Cancer</i> , 2016, 16, 734.	1.1	126
9	A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA- MONO/GOG-3020/ENGOT-ov45). <i>Journal of Clinical Oncology</i> , 2022, 40, 3952-3964.	0.8	125
10	Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent. <i>PLoS Medicine</i> , 2016, 13, e1002105.	3.9	118
11	Design and Development of ^{99m} Tc-Labeled FAPI Tracers for SPECT Imaging and ¹⁸⁸ Re Therapy. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1507-1513.	2.8	110
12	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. <i>Nature Communications</i> , 2014, 5, 4999.	5.8	105
13	Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1). <i>PLoS ONE</i> , 2017, 12, e0186043.	1.1	105
14	Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 699-709.	5.1	104
15	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. <i>Nature Communications</i> , 2016, 7, 11375.	5.8	93
16	The role of genetic breast cancer susceptibility variants as prognostic factors. <i>Human Molecular Genetics</i> , 2012, 21, 3926-3939.	1.4	80
17	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016, 7, 12675.	5.8	78
18	Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1. <i>American Journal of Human Genetics</i> , 2015, 96, 5-20.	2.6	76

#	ARTICLE	IF	CITATIONS
19	<i>BRCA2</i> Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. <i>Cancer Research</i> , 2017, 77, 2789-2799.	0.4	75
20	A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive <i>TP53</i>-mutant Ovarian Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4767-4776.	3.2	68
21	Genetic modifiers of CHEK2*1100delC-associated breast cancer risk. <i>Genetics in Medicine</i> , 2017, 19, 599-603.	1.1	67
22	TROPICS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2-metastatic breast cancer. <i>Future Oncology</i> , 2020, 16, 705-715.	1.1	62
23	Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE). <i>Journal of Clinical Oncology</i> , 2016, 34, 2516-2525.	0.8	60
24	Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 858-871.	5.1	60
25	Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation. <i>American Journal of Human Genetics</i> , 2016, 99, 903-911.	2.6	59
26	Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, <i>ERBB2</i>-Negative Advanced Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 1791.	3.4	56
27	Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer. <i>Investigational New Drugs</i> , 2018, 36, 848-859.	1.2	55
28	Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. <i>Human Molecular Genetics</i> , 2015, 24, 1478-1492.	1.4	50
29	Prognostic Cancer Gene Expression Signatures: Current Status and Challenges. <i>Cells</i> , 2021, 10, 648.	1.8	47
30	Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy. <i>European Journal of Cancer</i> , 2016, 53, 65-74.	1.3	46
31	The impact of human adipose tissue-derived stem cells on breast cancer cells: implications for cell-assisted lipotransfers in breast reconstruction. <i>Stem Cell Research and Therapy</i> , 2017, 8, 121.	2.4	43
32	COOLHAIR: a prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 135-143.	1.1	41
33	Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials. <i>European Journal of Cancer</i> , 2021, 148, 159-170.	1.3	41
34	Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. <i>Human Molecular Genetics</i> , 2015, 24, 2966-2984.	1.4	40
35	Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. <i>Human Molecular Genetics</i> , 2015, 24, 285-298.	1.4	38
36	Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. <i>American Journal of Human Genetics</i> , 2015, 97, 22-34.	2.6	37

#	ARTICLE	IF	CITATIONS
37	Breast Cancers with a <i>BRCA1</i> -like DNA Copy Number Profile Recur Less Often Than Expected after High-Dose Alkylating Chemotherapy. <i>Clinical Cancer Research</i> , 2015, 21, 763-770.	3.2	34
38	Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883). <i>Journal of Medical Genetics</i> , 2019, 56, 574-580.	1.5	34
39	DNA methylation array analysis identifies breast cancer associated <i>RPTOR</i> , <i>MGRN1</i> and <i>RAPSN</i> hypomethylation in peripheral blood DNA. <i>Oncotarget</i> , 2016, 7, 64191-64202.	0.8	33
40	An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating <i>IGFBP5</i> expression. <i>Human Molecular Genetics</i> , 2016, 25, 3863-3876.	1.4	33
41	Efficacy of nab-paclitaxel does not seem to be associated with <i>SPARC</i> expression in metastatic breast cancer. <i>Anticancer Research</i> , 2014, 34, 6609-15.	0.5	32
42	Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. <i>Oncotarget</i> , 2016, 7, 80140-80163.	0.8	31
43	Plasma hyaluronic acid level as a prognostic and monitoring marker of metastatic breast cancer. <i>International Journal of Cancer</i> , 2016, 138, 2499-2509.	2.3	31
44	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. <i>Breast Cancer Research</i> , 2016, 18, 64.	2.2	31
45	Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial. <i>International Journal of Cancer</i> , 2019, 144, 877-885.	2.3	31
46	Fibroblast growth factor receptor 4 gene (<i>FGFR4</i>) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer. <i>International Journal of Cancer</i> , 2012, 131, E586-91.	2.3	29
47	Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine. <i>Breast Cancer</i> , 2018, 25, 370-374.	1.3	28
48	The G protein-coupled estrogen receptor (<i>GPER/GPR30</i>) may serve as a prognostic marker in early-stage cervical cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 13-19.	1.2	27
49	Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2584-2591.	3.2	27
50	An international, biomarker-directed, randomized, phase II trial of AZD1775 plus paclitaxel and carboplatin (P/C) for the treatment of women with platinum-sensitive, TP53-mutant ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5506-5506.	0.8	26
51	<i>Mcl-1</i> confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications. <i>Breast Cancer Research</i> , 2016, 18, 26.	2.2	25
52	Fine-Scale Mapping of the 4q24 Locus Identifies Two Independent Loci Associated with Breast Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1680-1691.	1.1	24
53	Identification and Characterization of Cancer Cells That Initiate Metastases to the Brain and Other Organs. <i>Molecular Cancer Research</i> , 2021, 19, 688-701.	1.5	22
54	<i>CD24 Ala57Val</i> polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 819-831.	1.1	21

#	ARTICLE	IF	CITATIONS
55	Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. <i>Cancer Causes and Control</i> , 2016, 27, 679-693.	0.8	21
56	Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy. <i>Breast Cancer Research</i> , 2019, 21, 142.	2.2	21
57	SNP-SNP interaction analysis of NF- κ B signaling pathway on breast cancer survival. <i>Oncotarget</i> , 2015, 6, 37979-37994.	0.8	20
58	Diagnosis of Li-Fraumeni Syndrome: Differentiating TP53 germline mutations from clonal hematopoiesis. <i>Human Mutation</i> , 2018, 39, 2040-2046.	1.1	20
59	CD24 polymorphisms in breast cancer: impact on prognosis and risk. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 927-937.	1.1	19
60	The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns. <i>Epigenetics</i> , 2013, 8, 1226-1235.	1.3	19
61	Plasma S100P level as a novel prognostic marker of metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 329-338.	1.1	18
62	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016, 141, 386-401.	0.6	18
63	Clonal Hematopoiesis-Associated Gene Mutations in a Clinical Cohort of 448 Patients With Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 565-570.	3.0	17
64	BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophosphamide-thiotepa in high risk breast cancer patients randomized in the WSG-CAM01 trial. <i>International Journal of Cancer</i> , 2016, 139, 882-889.	2.3	16
65	Second breast conserving therapy after ipsilateral breast tumor recurrence – a 10-year experience of re-irradiation. <i>Journal of Contemporary Brachytherapy</i> , 2019, 11, 312-319.	0.4	15
66	Prophylaxis and Management of Skin Toxicities. <i>Breast Care</i> , 2019, 14, 72-77.	0.8	15
67	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. <i>Breast Cancer Research</i> , 2014, 16, R51.	2.2	14
68	Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer. <i>Carcinogenesis</i> , 2015, 36, 256-271.	1.3	14
69	Immunotherapy in Breast Cancer. <i>Oncology Research and Treatment</i> , 2016, 39, 335-345.	0.8	14
70	Prediction of pathological complete response in breast cancer patients during neoadjuvant chemotherapy: Is shear wave elastography a useful tool in clinical routine?. <i>European Journal of Radiology</i> , 2020, 128, 109025.	1.2	14
71	Bevacizumab-based treatment as salvage therapy in patients with recurrent symptomatic brain metastases. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa038.	0.4	14
72	Mismatch Repair Deficiency Drives Durable Complete Remission by Targeting Programmed Death Receptor 1 in a Metastatic Luminal Breast Cancer Patient. <i>Breast Care</i> , 2019, 14, 53-59.	0.8	13

#	ARTICLE	IF	CITATIONS
73	Neoadjuvant epirubicin, gemcitabine and docetaxel for primary breast cancer: Long-term survival data and major prognostic factors based on two consecutive neoadjuvant phase I/II trials. <i>International Journal of Cancer</i> , 2013, 133, 1006-1015.	2.3	12
74	Predictors of Residual Tumor in Breast-Conserving Therapy. <i>Annals of Surgical Oncology</i> , 2015, 22, 451-458.	0.7	12
75	Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. <i>PLoS ONE</i> , 2016, 11, e0160316.	1.1	12
76	First-in-human phase I/II dose-escalation study of IMAB027 in patients with recurrent advanced ovarian cancer (OVAR): Preliminary data of phase I part.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5537-5537.	0.8	12
77	Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor. <i>Clinical Cancer Research</i> , 2018, 24, 3358-3365.	3.2	11
78	Antibody-Drug Conjugates for Breast Cancer. <i>Oncology Research and Treatment</i> , 2022, 45, 26-36.	0.8	11
79	Treatment of Luminal Metastatic Breast Cancer beyond CDK4/6 Inhibition: Is There a Standard of Care in Clinical Practice?. <i>Breast Care</i> , 2021, 16, 115-128.	0.8	10
80	Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS602-TPS602.	0.8	10
81	A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial. <i>Clinical Cancer Research</i> , 2020, 26, 1896-1904.	3.2	9
82	Ovarian Cancer-specific BRCA-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 6559-6569.	3.2	9
83	Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium. <i>Human Genetics</i> , 2016, 135, 137-154.	1.8	8
84	Preclinical evaluation of peptide-based radiotracers for integrin $\alpha_6\beta_6$ -positive pancreatic carcinoma. <i>Nuklearmedizin - Nuclear Medicine</i> , 2019, 58, 309-318.	0.3	8
85	Utility of the CPS+EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy. <i>European Journal of Cancer</i> , 2021, 153, 203-212.	1.3	8
86	Clinical Relevance of Collagen Protein Degradation Markers C3M and C4M in the Serum of Breast Cancer Patients Treated with Neoadjuvant Therapy in the GeparQuinto Trial. <i>Cancers</i> , 2019, 11, 1186.	1.7	7
87	T-DM1 as a New Treatment Option for Patients with Metastatic HER2-positive Breast Cancer in Clinical Practice. <i>Anticancer Research</i> , 2015, 35, 5085-90.	0.5	7
88	A low-frequency haplotype spanning SLX4/FANCP constitutes a new risk locus for early-onset breast cancer (≤ 60 years) and is associated with reduced DNA repair capacity. <i>International Journal of Cancer</i> , 2018, 142, 757-768.	2.3	6
89	Potential Interplay of the Gatipotuzumab Epitope TA-MUC1 and Estrogen Receptors in Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 295.	1.8	6
90	Locoregional risk assessment after neoadjuvant chemotherapy in patients with primary breast cancer: clinical utility of the CPS+EG score. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 437-446.	1.1	5

#	ARTICLE	IF	CITATIONS
91	Prediction of local recurrence risk after neoadjuvant chemotherapy in patients with primary breast cancer: Clinical utility of the MD Anderson Prognostic Index. PLoS ONE, 2019, 14, e0211337.	1.1	5
92	Extracapsular Lymph Node Involvement in Ovarian Carcinoma. Cancers, 2019, 11, 924.	1.7	4
93	Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2). European Journal of Cancer, 2021, 156, 138-148.	1.3	4
94	Results of a phase II clinical trial to evaluate a re-challenge of intraperitoneal catumaxomab for treatment of malignant ascites (MA) due to epithelial cancer (SECIMAS).. Journal of Clinical Oncology, 2013, 31, 5582-5582.	0.8	4
95	A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA). Anti-Cancer Drugs, 2019, 30, 394-401.	0.7	3
96	The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial. Journal of Bone Oncology, 2019, 14, 100199.	1.0	3
97	PENELOPE/AGO-OVAR 2.20: A double-blind placebo (PLA)-controlled randomized phase III ENGOT trial evaluating chemotherapy (CT) with or without pertuzumab (P) for platinum-resistant ovarian cancer.. Journal of Clinical Oncology, 2014, 32, TPS5613-TPS5613.	0.8	3
98	Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum-resistant ovarian cancer (PROC): AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomized phase III trial.. Journal of Clinical Oncology, 2015, 33, 5504-5504.	0.8	3
99	AGO-OVAR 2.29 (ENGOT-ov34): Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer (ROC).. Journal of Clinical Oncology, 2019, 37, TPS5601-TPS5601.	0.8	3
100	NOGGO Ov-42/MAMOC: Rucaparib maintenance after bevacizumab maintenance following carboplatin-based first line-chemotherapy in ovarian cancer patients.. Journal of Clinical Oncology, 2020, 38, TPS6102-TPS6102.	0.8	3
101	TA-MUC1 as detected by the fully humanized, therapeutic antibody Gatipotzumab predicts poor prognosis in cervical cancer. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1899-1907.	1.2	2
102	Fibroblast growth factor receptor 4 (FGFR4) as detected by immunohistochemistry is associated with postoperative residual disease in ovarian cancer. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2251-2259.	1.2	2
103	Palbociclib combined with endocrine treatment in breast cancer patients with high relapse risk after neoadjuvant chemotherapy: Subgroup analyses of premenopausal patients in PENELOPE-B.. Journal of Clinical Oncology, 2021, 39, 518-518.	0.8	2
104	Incidence of germline mutations in risk genes including <i>BRCA1/2</i> in consecutive ovarian cancer (OC) patients (AGO TR-1).. Journal of Clinical Oncology, 2016, 34, 5538-5538.	0.8	2
105	DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status. Clinical Epigenetics, 2021, 13, 184.	1.8	2
106	Luminal Metastatic Breast Cancer. Breast Care, 2019, 14, 99-101.	0.8	1
107	What is the evidence for lymphadenectomy in presumed early ovarian cancer?. Archives of Gynecology and Obstetrics, 2019, 299, 1-5.	0.8	1
108	The PACOVAR-trial: A multicenter phase I trial of pazopanib (GW786034) and metronomic cyclophosphamide in patients with recurrent platinum-resistant ovarian cancer.. Journal of Clinical Oncology, 2015, 33, 5557-5557.	0.8	1

#	ARTICLE	IF	CITATIONS
109	COOLHAIR: A prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing neoadjuvant chemotherapy for early breast cancer.. Journal of Clinical Oncology, 2017, 35, 525-525.	0.8	1
110	BRCA1 like copy number profiles to predict benefit of intensified alkylating chemotherapy in breast cancer.. Journal of Clinical Oncology, 2013, 31, 11023-11023.	0.8	1
111	BRCA1-like copy number profiles to predict benefit of high-dose alkylating chemotherapy in high-risk breast cancer (BC): Results from randomized WSG AM-01 trial.. Journal of Clinical Oncology, 2014, 32, 11018-11018.	0.8	1
112	Correlation of the tumor mutational burden with the composition of the immune cell subpopulations in peripheral blood of triple-negative breast cancer patients undergoing neoadjuvant therapy with durvalumab: Results from the prospectively randomized GeparNuevo trial.. Journal of Clinical Oncology, 2019, 37, 588-588.	0.8	1
113	A randomized phase II trial of mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FR α)-high recurrent ovarian cancer eligible for platinum-based chemotherapy.. Journal of Clinical Oncology, 2022, 40, TPS5618-TPS5618.	0.8	1
114	OReO/ENGOT Ov-38 trial: Impact of maintenance olaparib rechallenge according to ovarian cancer patient prognosisâ€”An exploratory joint analysis of the BRCA and non-BRCA cohorts.. Journal of Clinical Oncology, 2022, 40, 5558-5558.	0.8	1
115	Neoadjuvant epirubicin, gemcitabine, and docetaxel for primary breast cancer: Survival and prognostic factors in two consecutive neoadjuvant phase I/II trials.. Journal of Clinical Oncology, 2012, 30, 1096-1096.	0.8	0
116	Circulating tumor cells in metastatic breast cancer: Are they a strong and independent predictor of poor progression-free and overall survival?. Journal of Clinical Oncology, 2012, 30, 1090-1090.	0.8	0
117	Prognostic impact of changes in circulating tumor cells (CTC) in metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2013, 31, 11012-11012.	0.8	0
118	Expression of SPARC and response to nab-paclitaxel (nab-p) in patients (pts) with metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2014, 32, e12009-e12009.	0.8	0
119	Interim analysis of a phase I/II open label, dose-escalating study to investigate safety, tolerability, and preliminary efficacy of the trifunctional anti-HER2/neu x anti-CD3 antibody ertumaxomab in patients with HER2/neu expressing solid tumors progressing after standard therapy.. Journal of Clinical Oncology, 2014, 32, 3055-3055.	0.8	0
120	DNA methylation array analyses to identify HYAL2 methylation in peripheral blood as a marker for the detection of early breast cancer.. Journal of Clinical Oncology, 2014, 32, 26-26.	0.8	0
121	Predictive value of ultra-high ESR1 mRNA expression in early breast cancer.. Journal of Clinical Oncology, 2016, 34, e12045-e12045.	0.8	0
122	Comparison of an automated cartridge-based system for mRNA assessment with central immunohistochemistry in the neoadjuvant GeparX trial.. Journal of Clinical Oncology, 2019, 37, 3075-3075.	0.8	0
123	Abstract P5-13-36: Germline <i>BRCA1/2</i> and other predisposition genes in high-risk early-stage HR+/HER2- breast cancer (BC) patients treated with endocrine therapy (ET) with or without palbociclib: A secondary analysis from the PENELOPE-B study. Cancer Research, 2022, 82, P5-13-36-P5-13-36.	0.4	0
124	Abstract PD2-04: Molecular plasticity of luminal breast cancer and response to CDK 4/6 inhibition - The biomarker program of the PENELOPE-B trial investigating post-neoadjuvant palbociclib. Cancer Research, 2022, 82, PD2-04-PD2-04.	0.4	0
125	AGO-OVAR 2.29 (ENGOT-ov34): Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer (ROC).. Journal of Clinical Oncology, 2022, 40, TPS5611-TPS5611.	0.8	0